Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias

Clinical Biochemistry

Volumn 41, Issue 16-17, 2008, Pages 1377-1383

  Ostrowska, Halina ^a   Hempel, Dominika ^a   Holub, Malgorzata ^a   Sokolowski, Jaroslaw ^a   Kloczko, Janusz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chymotrypsin like activity; Leukemia; Plasma; Proteasome

Indexed keywords

ANTINEOPLASTIC AGENT; CHYMOTRYPSIN; DODECYL SULFATE SODIUM; PROTEASOME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHYMOTRYPSIN; FEMALE; HUMANS; HYDROLYSIS; L-LACTATE DEHYDROGENASE; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; SODIUM DODECYL SULFATE;

EID: 55049102904     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.08.063     Document Type: Article

References (31)

1. Coux O., Tanaka K., and Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Ann. Rev. Biochem. 65 (1996) 801-847
2. Baumeister W., Dahlmann B., Hergel R., Kopp F., Kuehn L., and Pfeifer G. Electron microscopy and image analysis of the multicatalytic proteinase. FEBS. Letters 241 (1988) 239-245
3. Groll M., and Huber R. Inhibitors of eukaryotic 20S proteasome core particle: a structural approach. Biochim. Biophys. Acta. 1695 (2004) 33-44
4. Orlowski M., and Wilk S. Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Archiv. Biochem. Biophys. 383 (2000) 1-16
5. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2001) 373-428
6. Kloetzel P.M., and Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16 (2004) 76-81
7. Orlowski Z. The ubiquitin proteasome pathway from bench to bedside. Hematology 1 (2005) 220-225
8. Voorhees P.M., and Orlowski R.Z. The proteasome and proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 189-213
9. Kumatori A., Tanaka K., Inamura N., et al. Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. USA. 87 (1990) 7071-7075
10. Kisselev A.F., and Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8 (2001) 739-758
11. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61 (2001) 3071-3076
12. Adams J. Proteasome inhibitors as new anticancer drugs. Curr. Opin. Oncol. 14 (2002) 628-634
13. Pahler J.C., Ruiz S., Niemer I., et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin. Cancer Res. 9 (2003) 4570-4577
14. Adams J., and Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22 (2004) 304-311
15. Vink J., Cloos J., and Kaspers G.J.L. Proteasome inhibition as novel treatment strategy in leukaemia. Br. J. Haematol. 134 (2006) 253-262
16. Wada M., Kosaka M., Saito S., Sano T., Tanaka K., and Ichihara A. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J. Lab. Clin. Med. 121 (1993) 215-223
17. Lavabre-Bertrand T., Henry L., Carillo S., et al. Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer 92 (2001) 2493-2500
18. Dutaud D., Aubry L., Henry L., et al. Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J. Immunol. Methods 260 (2002) 183-193
19. Jakob C., Egerer K., Liebisch P., et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 109 (2007) 2100-2103
20. Stoebner P.E., Lavabre-Bertrand T., Henry L., et al. High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br. J. Dermatol. 152 (2005) 948-953
21. Shibatani T., and Ward W.F. Sodium dodecyl sulfate (SDS) activation of the 20S proteasome in rat liver. Arch. Biochem. Biophys. 321 (1995) 160-166
22. Lightcap E.S., McCormack T.A., Pien C.h.S., Chau V., Adams J., and Elliott P.J. Proteasome inhibition measurements: clinical application. Clin. Chem. 46 (2000) 673-683
23. Reed J.C. Molecular biology of chronic lymphocytic leukemia. Semin. Oncol. 25 (1998) 11-18
24. Kornberg A., and Polliack A. Serum lactic dehydrogenase (LDH) levels in acute leukemia: marked elevations in lymphoblastic leukemia. Blood 56 (1980) 351-355
25. Ma W., Kantarjian H., O'Brien S., et al. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 112 (2008) 1306-1312
26. Bradford M.M. A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
27. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
28. Zoeger A., Blau M., Egerer K., Feist E., and Dahlmann B. Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin. Chem. 52 (2006) 2079-2086
29. Silva Pereira I., Bey F., Coux O., and Scherrer K. Two mRNAs exist for the Hs PROS-30 gene encoding a component of human prosomes. Gene 120 (1992) 235-242
30. Carrard G., Dieu M., Raes M., Toussaint O., and Friguet B. Impact of aging on proteasome structure and function in human lymphocytes. Int. J. Biochem. Cell Biol. 35 (2003) 728-739
31. Egerer K., Kuckelkorn U., Rudolph P.E., et al. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J. Rheumatol. 29 (2002) 2045-2052